TL;DR
Recent advances at the interface of AI and antibody drug discovery are highlighted, key methodological developments are discussed, and the challenges that remain in translating AI-driven strategies into clinical success are examined.
This study reviews AI-driven drug discovery methods, presents a structured AI pipeline from data collection to candidate selection, and evaluates performance using metrics such as prediction accuracy, screening efficiency, lead optimization success, and toxicity reduction.
AutoML mitigates issues by automating key stages of the ML pipeline data preprocessing, model selection, hyperparameter tuning, and evaluation thereby enhancing scalability and reducing dependence on domain expertise.
This review examines how machine learning, deep learning, natural language processing (NLP), and generative modeling are being applied across medicinal chemistry and drug development, and highlights how multimodal data fusion, predictive modeling, and human-AI collaborative frameworks are supporting more informed decis...
This review emphasizes the influence of new AI platforms like AlphaFold3, molecular interactions are structurally optimized (MISATO), and ZairaChem on the discovery of oncology drugs and examines how AI reconciles chemical design with pharmacological feasibility.
This review highlights the synergy between AI and HTS, emphasizing DL techniques such as convolutional neural networks for bioactivity prediction, recurrent neural networks for de novo design, and reinforcement learning for property optimization.
It is demonstrated that this AI-driven paradigm is essential for advancing precision medicine, as it systematically translates vast and heterogeneous datasets into testable mechanistic hypotheses, and accelerates the development of safer, more effective and patient-specific therapies.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
